Page last updated: 2024-11-02

pca 4248 and Leukocyte Disorders

pca 4248 has been researched along with Leukocyte Disorders in 1 studies

PCA 4248: structure given in first source; platelet activating factor antagonist

Leukocyte Disorders: Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells.

Research Excerpts

ExcerptRelevanceReference
"Zymosan-induced articular hyperalgesia, oedema and neutrophil migration were dose-dependently reduced following pretreatment with selective PAFR antagonists, UK74505 (5, 10 and 20 mg/kg) and PCA4248 (3, 10, 30 mg/kg)."1.39The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia. ( Cunha, FQ; Cunha, TM; Ferreira, SH; Guerrero, AT; Pinto, LG; Verri, WA; Vieira, SM; Zaperlon, AC; Zarpelon, AC, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guerrero, AT1
Zarpelon, AC1
Zaperlon, AC1
Vieira, SM1
Pinto, LG1
Ferreira, SH1
Cunha, FQ1
Verri, WA1
Cunha, TM1

Other Studies

1 other study available for pca 4248 and Leukocyte Disorders

ArticleYear
The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia.
    Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:1

    Topics: Animals; Dihydropyridines; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; I

2013